Janux Therapeutics, Inc. (JANX) Tops Q3 EPS by 23c

Janux Therapeutics, Inc. (NASDAQ: JANX) reported Q3 EPS of ($0.39), $0.23 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $10 million versus the consensus estimate of $2.88 million.

For earnings history and earnings-related data on Janux Therapeutics, Inc. (JANX) click here.

You May Also Be Interested In

• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Contango Silver & Gold starts drilling at Lucky Shot, updates on key projects
• ADP weekly jobs estimate rises to 30,750 for week ending June 6